[ CAS No. 1986-47-6 ] {[proInfo.proName]}

Name: 1986-47-6|trans-2-Phenylcyclopropanamine hydrochloride|97%
Brand: Ambeed
SKU: A116070
Price: 5.0 USD
Availability: InStock
Rating: 97 (27 reviews)

,{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]}

HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type	HazMat fee for 500 gram (Estimated)
Excepted Quantity	USD 0.00
Limited Quantity	USD 15-60
Inaccessible (Haz class 6.1), Domestic	USD 80+
Inaccessible (Haz class 6.1), International	USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic	USD 100+
Accessible (Haz class 3, 4, 5 or 8), International	USD 200+

2D 3D

Structure of 1986-47-6 * Storage: {[proInfo.prStorage]}

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

For Research Only 110K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 1986-47-6 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 1986-47-6 ]

SDS Specification

Alternatived Products of [ 1986-47-6 ]

Product Details of [ 1986-47-6 ]

CAS No. :	1986-47-6	MDL No. :	MFCD00063602
Formula :	C₉H₁₂ClN	Boiling Point :	-
Linear Structure Formula :	-	InChI Key :	-
M.W :	169.65	Pubchem ID :	-
Synonyms :	SKF 385 hydrochloride;Tranylcypromine (hydrochloride);trans-2-Phenylcyclopropylamine;2-PCPA;Tranylcypromine HCl	Chemical Name :	trans-2-Phenylcyclopropanamine hydrochloride

Calculated chemistry of [ 1986-47-6 ]

Physicochemical Properties

Num. heavy atoms :	11
Num. arom. heavy atoms :	6
Fraction Csp3 :	0.33
Num. rotatable bonds :	1
Num. H-bond acceptors :	1.0
Num. H-bond donors :	1.0
Molar Refractivity :	48.58
TPSA :	26.02 Å²

Pharmacokinetics

GI absorption :	High
BBB permeant :	Yes
P-gp substrate :	No
CYP1A2 inhibitor :	No
CYP2C19 inhibitor :	No
CYP2C9 inhibitor :	No
CYP2D6 inhibitor :	No
CYP3A4 inhibitor :	No
Log Kp (skin permeation) :	-5.71 cm/s

Lipophilicity

Log Po/w (iLOGP) :	0.0
Log Po/w (XLOGP3) :	2.29
Log Po/w (WLOGP) :	2.3
Log Po/w (MLOGP) :	2.1
Log Po/w (SILICOS-IT) :	1.83
Consensus Log Po/w :	1.7

Druglikeness

Lipinski :	0.0
Ghose :	None
Veber :	0.0
Egan :	0.0
Muegge :	2.0
Bioavailability Score :	0.55

Water Solubility

Log S (ESOL) :	-2.67
Solubility :	0.361 mg/ml ; 0.00213 mol/l
Class :	Soluble
Log S (Ali) :	-2.47
Solubility :	0.57 mg/ml ; 0.00336 mol/l
Class :	Soluble
Log S (SILICOS-IT) :	-2.37
Solubility :	0.719 mg/ml ; 0.00424 mol/l
Class :	Soluble

Medicinal Chemistry

PAINS :	0.0 alert
Brenk :	0.0 alert
Leadlikeness :	1.0
Synthetic accessibility :	1.69

Safety of [ 1986-47-6 ]

Signal Word:	Danger	Class:	6.1
Precautionary Statements:	P501-P270-P264-P301+P310+P330-P405	UN#:	2811
Hazard Statements:	H301	Packing Group:	Ⅲ
GHS Pictogram:

Application In Synthesis of [ 1986-47-6 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Upstream synthesis route of [ 1986-47-6 ]
Downstream synthetic route of [ 1986-47-6 ]

[ 1986-47-6 ] Synthesis Path-Upstream 1~2

1
[ 939-90-2 ]
[ 1986-47-6 ]

Reference： [1] Journal of Medicinal Chemistry, 1996, vol. 39, # 7, p. 1485 - 1493
[2] Bioorganic and Medicinal Chemistry, 2009, vol. 17, # 6, p. 2388 - 2399
[3] Angewandte Chemie - International Edition, 2018, vol. 57, # 30, p. 9501 - 9504[4] Angew. Chem., 2018, vol. 130, # 30, p. 9645 - 9648,4

2
[ 5861-31-4 ]
[ 1986-47-6 ]

Reference： [1] Journal of Medicinal Chemistry, 1996, vol. 39, # 7, p. 1485 - 1493

[ 1986-47-6 ] Synthesis Path-Downstream 1~88

1
[ 22118-09-8 ]
[ 1986-47-6 ]
[ 133941-07-8 ]

Reference： [1]Journal of Pharmaceutical Sciences,1991,vol. 80,p. 255 - 261

2
[ 20260-53-1 ]
[ 1986-47-6 ]
[ 133941-05-6 ]

Reference： [1]Journal of Pharmaceutical Sciences,1991,vol. 80,p. 255 - 261

3
[ 109822-09-5 ]
[ 1986-47-6 ]
[ 133941-11-4 ]

Reference： [1]Journal of Pharmaceutical Sciences,1991,vol. 80,p. 255 - 261

4
[ 1986-47-6 ]
[ 21087-29-6 ]
[ 4407-36-7 ]

Reference： [1]Journal of Organic Chemistry,1984,vol. 49,p. 4560 - 4562

5
[ 1986-47-6 ]
[ 22128-62-7 ]
[ 133941-13-6 ]

Reference： [1]Journal of Pharmaceutical Sciences,1991,vol. 80,p. 255 - 261

6
[ 1986-47-6 ]
[ 4801-27-8 ]
[ 133941-14-7 ]

Reference： [1]Journal of Pharmaceutical Sciences,1991,vol. 80,p. 255 - 261

7
[ 1986-47-6 ]
[ 107-08-4 ]
((1R,2S)-2-Phenyl-cyclopropyl)-dipropyl-amine [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,1996,vol. 39,p. 1485 - 1493

8
((1SR,2RS)-tert-butyl-2-phenylcyclopropyl)carbamate [ No CAS ]
[ 1986-47-6 ]

Reference： [1]Journal of the American Chemical Society,2010,vol. 132,p. 6827 - 6833
[2]Journal of Medicinal Chemistry,1996,vol. 39,p. 1485 - 1493

9
[ 1986-47-6 ]
2-methyl-2,3-diphenyl-3,4-dihydro-2H-pyrrole [ No CAS ]

Reference： [1]Organic Letters,2001,vol. 3,p. 4087 - 4089

10
[ 1986-47-6 ]
[ 60106-90-3 ]

Reference： [1]European Journal of Medicinal Chemistry,2000,vol. 35,p. 599 - 618

11
[ 1986-47-6 ]
N-methyl-2-methylamino-3-naphthalen-2-yl-N-(2-phenyl-cyclopropyl)-propionamide [ No CAS ]

Reference： [1]European Journal of Medicinal Chemistry,2000,vol. 35,p. 599 - 618

12
[ 1986-47-6 ]
methyl-{1-[methyl-(2-phenyl-cyclopropyl)-carbamoyl]-2-naphthalen-2-yl-ethyl}-carbamic acid tert-butyl ester [ No CAS ]

Reference： [1]European Journal of Medicinal Chemistry,2000,vol. 35,p. 599 - 618

13
[ 1986-47-6 ]
(E)-5-Amino-5-methyl-hex-2-enoic acid methyl-{(R)-1-[methyl-(2-phenyl-cyclopropyl)-carbamoyl]-2-naphthalen-2-yl-ethyl}-amide [ No CAS ]

Reference： [1]European Journal of Medicinal Chemistry,2000,vol. 35,p. 599 - 618

14
[ 1986-47-6 ]
[(E)-1,1-Dimethyl-4-(methyl-{(R)-1-[methyl-(2-phenyl-cyclopropyl)-carbamoyl]-2-naphthalen-2-yl-ethyl}-carbamoyl)-but-3-enyl]-carbamic acid tert-butyl ester [ No CAS ]

Reference： [1]European Journal of Medicinal Chemistry,2000,vol. 35,p. 599 - 618

15
[ 939-90-2 ]
[ 1986-47-6 ]

Reference： [1]Journal of Medicinal Chemistry,1996,vol. 39,p. 1485 - 1493
[2]Bioorganic and Medicinal Chemistry,2009,vol. 17,p. 2388 - 2399
[3]Angewandte Chemie - International Edition,2018,vol. 57,p. 9501 - 9504
Angew. Chem.,2018,vol. 130,p. 9645 - 9648,4

16
[ 5861-31-4 ]
[ 1986-47-6 ]

Reference： [1]Journal of Medicinal Chemistry,1996,vol. 39,p. 1485 - 1493

17
[ 103-26-4 ]
paraformaldehyde [ No CAS ]
[ 1986-47-6 ]

Reference： [1]Journal of Medicinal Chemistry,1996,vol. 39,p. 1485 - 1493

18
[ 1986-47-6 ]
(+/-)-trans-2-oxo-2-<(2-phenylcyclopropyl)amino>ethyl-3-pyridinecarboxylate [ No CAS ]

Reference： [1]Journal of Pharmaceutical Sciences,1991,vol. 80,p. 255 - 261

19
[ 1986-47-6 ]
[ 133941-15-8 ]

Reference： [1]Journal of Pharmaceutical Sciences,1991,vol. 80,p. 255 - 261

20
[ 1986-47-6 ]
[ 133941-12-5 ]

Reference： [1]Journal of Pharmaceutical Sciences,1991,vol. 80,p. 255 - 261

21
[ 1986-47-6 ]
[ 133941-16-9 ]

Reference： [1]Journal of Pharmaceutical Sciences,1991,vol. 80,p. 255 - 261

22
[ 2510-37-4 ]
[ 1986-47-6 ]
C₁₅H₁₆N₂O₂ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With O-[(ethoxycarbonyl)cyanomethyleneamino]-N,N,N',N'-tetramethyluronium tetrafluoroborate; N-ethyl-N,N-diisopropylamine; In DMF (N,N-dimethyl-formamide); at 0 - 20℃; for 24.5h;	304 mg (0.928 mmol, 1.05 equivalents) of TOTU and 323 mul (1.857 mmol, 2.1 equivalents) of ethyldiisopropylamine were added to 0.973 mmol (1.0 equivalent) of the respective carboxylic acid in 2 ml of absolute dimethylformamide at 0C and the mixture was stirred for 20 minutes at 0C. Subsequently, 0.884 mmol (1.0 equivalent) of the respective arylcycloalkylamine hydrochloride, dissolved in 2 ml of absolute dimethylformamide, were added and the mixture was stirred for 30 minutes at 0C and for 24 h at room temperature. The reaction mixture was filtered, the filter cake washed with 20 ml of ethyl acetate and the resulting solution washed with 20 ml of 5% aqueous sodium hydrogencarbonate solution and 20 ml of 5% aqueous sodium chloride solution. The organic phase was dried over Chromabond XTR and evaporated. The obtained raw product was purified by preparative HPLC (RP-18, acetonitrile/water + 0.1 % trifluoroacetic acid).

Reference： [1]Patent: EP1388535,2004,A1 .Location in patent: Page 14-15

23
[ 1986-47-6 ]
[ 100-52-7 ]
(1S*,2R*)-N-benzyl-2-phenylcyclopropan-1-amine [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
54%		General procedure: Trans-2-phenylcyclopropylamine hydrochloride (1.0 eq.), acetic acid (1.0eq.) and the appropriate aldehyde (0.9 eq.) were dissolved in around bottom flask in 10 mL dry DCE. The reaction mixture was stirred gently at room temperature for 2 h before sodium triacetoxyborohydride (3.0 eq.) was added in small portions to the reaction vessel. The reaction was monitored by TLC and quenched using 10 mL of an aqueous (5%) NaHCO3 solution. The organic layer was separated and the aqueous layer extracted three times with10 mL of DCE. All organic layers were combined, dried over anhydrous Na2SO4, concentrated in vacuo and purified using flash chromatography (silica gel; cyclohexane/ethyl acetate) to give the desired compound.
		Example 7: frans-(+/-)-Benzyl-(2-phenyl-cyclopropyl)-amine 11; [000204] To a stirred solution of trans-(+/-)-2-Phenylcyclopropylamine hydrochloride (50 mg, 0.295 mmol) in MeOH (1 ml_) were added benzaldehyde (27 uL, 0.266 mmol) and sodium cyanoborohydride (22 mg, 0.354 mmol). The mixture was stirred at 0 C for 1 h followed at room temperature overnight. To the reaction mixture was added crushed ice, and the acetonitril was removed under vacuum. The aqueous residue was extracted with CH2CI2. The combined organic layers were dried over Na2SO4, filtered, and concentrated. The residue was purified by preparative TLC using a mixture of EtOAc/Et3N (95:5) as a developing solvent to afford the title compound as a colorless oil (15.4 mg). 1H NMR (CDCI3): delta (ppm) 7.40-7.25 (m, 9 H), 7.18 (m, 1 H), 7.03 (d, 2 H, J = 7.3 Hz), 3.92 (s, 2 H), 2.42 (m, 1 H), 2.25 (m, br. s, 1 H), 1.97 (m, 1 H), 1.14 (m, 1 H), 1.01 (m, 1 H). 13C NMR (CDCI3): delta (ppm) 142.7, 140.7, 128.8 (2), 128.7 (2), 128.6 (2), 127.4, 126.3 (2), 125.9, 54.0, 41.6, 25.8, 17.5. HRMS (ESI) calculated for Ci6Hi8N+ [MH+] 224.1439; found, 224.1440.

Reference： [1]European Journal of Medicinal Chemistry,2018,vol. 144,p. 52 - 67
[2]Patent: WO2007/25144,2007,A1 .Location in patent: Page/Page column 35; 78

24
[ 1986-47-6 ]
[ 2258-42-6 ]
N-((1R*,2S*)-2-phenylcyclopropyl)formamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With 4-methyl-morpholine; In tetrahydrofuran; at -15 - 20℃; for 1.5h;	Example 3: Preparation of trans-(+/-)-Methyl-(2-phenyl-cyclopropyl)-amine; 7[000199] Acetic formic anhydride was generated by dropwise addition of formic acid (0.36 mL, 9.6 mmol) to acetic anhydride ( 0.73 ml_, 7.8 mmol) maintained on ice followed at 50 C for 2 h. The mixture was cooled to room temperature, and THF (5 mL) was added. This mixture (0.6 mL) containing acetic formic anhydride (0.3 mmol) was added to a solution of trans-(+/-)-2-phenyl-cyclopropylamine hydrochloride (50 mg, 0.3 mmol) in THF (1 mL) at -15 C followed by addition of Lambda/-methylmorpholine (45 uL, 0.3 mmol). The resulting mixture was stirred at -15 C for 30 min and at room temperature for 1 h, filtered out insoluble materials, and concentrated in vacuo. The crude residue (65 mg) was dissolved in THF (1.2 mL), and to the solution was added 1.0 M solution of borane dimethylsulfide complex in THF (0.75 mL). After the mixture was stirred at 65 C overnight, the reaction was quenched by 10% aqueous HCI. The mixture was concentrated under reduced pressure to remove THF, and the residual aqueous solution was washed with Et2theta (x1), neutralized with 10% aqueous NaOH, and then extracted with Et2O (x3). The combined organic layers were dried over Na2SO4, filtered, and concentrated. The residue was purified by preparative TLC using a mixture of EtOAc/Et3N/MeOH (8:1:1) as a developing solvent to afford the title compound as a colorless oil (21 mg). 1H NMR (CDCI3): delta (ppm) 7.30-7.25 (m, 2 H), 7.20-7.16 (m, 1 H), 7.09-7.06 (m, 2 H), 2.54 (br. s, 3 H), 2.34 (m, 1 H), 1.92 (m, 1 H), 1.76 (br. s, 1 H), 1.12-1.06 (m, 1 H), 1.02-0.98 (m, 1 H). 13C NMR (CDCI3): delta (ppm) 142.8, 128.6 (2), 126.3 (2), 125.9, 43.7, 36.2, 25.3, 17.5. HRMS (ESI) calculated for C10Hi4N+ [MH+] 148.1126; found, 148.1124.

Reference： [1]Patent: WO2007/25144,2007,A1 .Location in patent: Page/Page column 35; 75

25
[ 1986-47-6 ]
[ 2258-42-6 ]
C₁₁H₁₃NO [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With 4-methyl-morpholine; In tetrahydrofuran; at -15 - 20℃; for 1.5h;	Example 4: fra/7s-(+/-)-Methyl-(2-phenyl-cyclopropylmethyl)-amine; 8[000200] Acetic formic anhydride was generated by dropwise addition of formic acid (0.18 mL, 4.8 mmol) to acetic anhydride ( 0.365 ml_, 3.9 mmol) maintained on ice followed at 50 C for 2 h. The mixture was cooled to room temperature, and THF (4.5 mL) was added. This mixture (0.53 mL) containing acetic formic anhydride (0.408 mmol) was added to a solution of trans-(+/-)-2-phenyl-cyclopropylmethylamine hydrochloride (30 mg, 0.163 mmol) in THF (1 mL) at -15 C followed by addition of Lambda/-methylmorpholine (17.9 uL, 0.163 mmol). The resulting mixture was stirred at -15 "C for 30 min and at room temperature for 1 h, filtered out insoluble materials, and concentrated in vacuo.[000201] The crude residue (42 mg) was dissolved in THF (1.2 mL), and to the solution was added 1.0 M solution of borane dimethylsulfide complex in THF (0.41 mL). After the mixture was stirred at 65 C overnight, the reaction was quenched by 10% aqueous HCI. The mixture was concentrated under reduced pressure to remove THF, and the residual aqueous solution was washed with Et2O (x1), neutralized with 10% aqueous NaOH, and then extracted with Et2O (x3). The combined organic layers were dried over Na2SO4, filtered, and concentrated. The residue was purified by preparative TLC using a mixture of EtOAc/Et.3N/MeOH (8:1:1) as a developing solvent to afford the title compound as a colorless oil (14.0 mg). 1H NMR (CDCI3):delta (ppm) 7.29-7.24 (m, 2 H), 7.18-7.15 (m, 1 H), 7.10-7.07 (m, 2 H), 2.66 (br. d, 2 H), 2.49 (br. s, 3 H), 2.37 (br. s, 1 H), 1.77 (m, 1 H), 1.38-1.32 (m, 1 H), 0.99-0.85 (m, 2 H). 13C NMR (CDCI3): delta (ppm) 143.3, 128.7, 126.2, 125.9, 56.5, 36.5, 23.3, 22.5, 15.1. HRMS (ESI) calculated for CnH16N+ [MH+] 162.1283; found, 162.1285.

Reference： [1]Patent: WO2007/25144,2007,A1 .Location in patent: Page/Page column 35; 76

26
[ 50-00-0 ]
[ 1986-47-6 ]
[ 14177-80-1 ]

Yield	Reaction Conditions	Operation in experiment
	With 4-methyl-morpholine; sodium cyanoborohydride; acetic acid; In water; acetonitrile; at 20℃; for 0.666667h;	Example 5: frans-(+/-)-Dimethyl-(2-phenyl-cyclopropyl)-amine; 9[000202] To a stirred solution of fra/7s-(+/-)-2-Phenylcyclopropylamine hydrochloride (34 mg, 0.2 mmol) in acetonitrile/H2theta (1 :1 , v/v) (5 ml_) were added N- methylmorpholine (45 uL, 0.4 mmol), 37% aqueous formaldehyde (0.16 mL, 2.0 mmol), and sodium cyanoborohydride (40 mg, 0.6 mmol). Glacial acetic acid (40 uL) was added to the mixture over 10 min and the reaction was stirred at room temperature for 30 min. To the reaction mixture was added crushed ice, and the acetonitrile was removed under vacuum. The aqueous residue was extracted with CH2CI2. The combined organic layers were dried over Na2SO4, filtered, and concentrated. The residue was purified by preparative TLC using a mixture of EtOAc/Et3N (95:5) as a developing solvent to afford the title compound as a colorless oil (19.7 mg). 1H NMR (CDCI3): delta (ppm) 7.34-7.26 (m, 2 H), 7.18 (t, 1 H, J = 7.3 Hz), 7.09 (d, 2 H, J = 7.2 Hz), 2.74 (d, 2 H, J = 3.6 Hz), 2.42 (s, 6 H), 2.00 (m, 1 H), 1.83 (m, 1 H), 1.13 (m, 1 H), 0.99 (m, 1 H). 13C NMR (CDCI3): delta (ppm) 142.5, 128.6 (2), 126.5 (2), 126.0, 50.6, 45.4 (2), 25.7, 17.6. HRMS (ESI) calculated for CnH16N+ [MH+] 162.1283; found, 162.1279.

Reference： [1]Patent: WO2007/25144,2007,A1 .Location in patent: Page/Page column 35; 77

27
[ 1986-47-6 ]
[ 67-64-1 ]
trans-N-isopropyl-(2-phenylcyclopropyl)amine [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
		Example 6: Preparation of trans-(+/-)-lsopropyl-(2-phenyl-cyclopropyl)-amine 10; [000203] To a stirred solution of trans-(+/-)-2-Phenylcyclopropylamine hydrochloride (50 mg, 0.295 mmol) in MeOH (1 mL) were added acetone (21.7 uL, 0.295 mmol) and sodium cyanoborohydride (22 mg, 0.354 mmol). The mixture was stirred at 0 C for 1 h followed at room temperature overnight. To the reaction mixture was added EPO <DP n="79"/>crushed ice, and the acetonitril was removed under vacuum. The aqueous residue was extracted with CH2CI2. The combined organic layers were dried over Na2SO4, filtered, and concentrated. The residue was purified by preparative TLC using a mixture of EtOAc/Et3N (95:5) as a developing solvent to afford the title compound as a colorless oil (16.7 mg). 1H NMR (CDCI3): delta (ppm) 7.30-7.25 (m, 2 H), 7.19-7.14 (m, 1 H), 7.06 (d, 2 H, J = 7.3 Hz), 3.01 (m, 1 H), 2.31 (m, 1 H), 1.90 (m, 1 H), 1.87 (br. s, 1 H), 1.12 (d, 6 H, J = 6.3 Hz), 1.07 (m, 2 H). 13C NMR (CDCI3): delta (ppm) 142.8, 128.6 (2), 126.1 (2), 125.8, 49.7, 40.7, 25.9, 23.7, 23.6, 17.2. HRMS (ESI) calculated for Ci2H18N+ [MH+] 176.1439; found, 176.1437.

Reference： [1]Patent: WO2007/25144,2007,A1 .Location in patent: Page/Page column 35; 77-78

28
[ 1986-47-6 ]
[ 129765-95-3 ]
C₁₉H₂₈N₂O₃ [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,2009,vol. 17,p. 2388 - 2399

29
[ 619-65-8 ]
[ 1986-47-6 ]
4-cyano-N-(trans-2-phenylcyclopropyl)benzamide [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2011,vol. 54,p. 851 - 857

30
[ 32178-63-5 ]
[ 1986-47-6 ]
8-methoxy-N-(trans-2-phenylcyclopropyl)-1,2,3,4-tetrahydronaphthalen-2-carboxamide [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2011,vol. 54,p. 851 - 857

31
[ 1986-47-6 ]
[ 19155-88-5 ]
N-(trans-2-phenylcyclopropyl)benzo[c][1,2,5]oxadiazole-5-carboxamide [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2011,vol. 54,p. 851 - 857

32
[ 33233-67-9 ]
[ 1986-47-6 ]
C₂₂H₂₆N₂O₃ [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2012,vol. 55,p. 1346 - 1359

33
[ 1986-47-6 ]
C₁₇H₁₈N₂O [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2012,vol. 55,p. 1346 - 1359

34
[ 1986-47-6 ]
N-(trans-2-phenylcyclopropyl)-4-[[(2-chloro-6-methylquinazolin-4-yl)amino]methyl]benzamide [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2012,vol. 55,p. 1346 - 1359

35
[ 1986-47-6 ]
N-(trans-2-phenylcyclopropyl)-4-[[(2-(dimethylamino)-6-methylquinazolin-4-yl)amino]methyl]benzamide [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2012,vol. 55,p. 1346 - 1359

36
[ 1986-47-6 ]
N-(trans-2-phenylcyclopropyl)-4-[[(2-(ethylamino)-6-methylquinazolin-4-yl)amino]methyl]benzamide [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2012,vol. 55,p. 1346 - 1359

37
trans-N-(2-phenylcyclopropyl)pivalamide [ No CAS ]
[ 1986-47-6 ]

Reference： [1]Organic and Biomolecular Chemistry,2016,vol. 14,p. 8576 - 8585
[2]Angewandte Chemie - International Edition,2015,vol. 54,p. 846 - 851
Angew. Chem.,2014,vol. 127,p. 860 - 865,6

38
[ 1986-47-6 ]
[ 1986-47-6 ]

Reference： [1]Angewandte Chemie - International Edition,2015,vol. 54,p. 846 - 851
Angew. Chem.,2014,vol. 127,p. 860 - 865,6

39
[ 1986-47-6 ]
N-((1R,2S)-2-phenylcyclopropyl)pivalamide [ No CAS ]

Reference： [1]Angewandte Chemie - International Edition,2015,vol. 54,p. 846 - 851
Angew. Chem.,2014,vol. 127,p. 860 - 865,6

40
[ 1986-47-6 ]
tert-butyl 4-(cyanomethyl)-4-(3-[(trans-2-phenylcyclopropyl)(trifluoroacetyl)amino]methyl}azetidin-1-yl)piperidine-1-carboxylate [ No CAS ]